Contact Us

Yes. ESYT2 rescue experiments require attention to ER-PM contact site architecture: • Construct design: use a codon-modified ESYT2 sequence with a small C-terminal tag (FLAG, HA). ESYT2 has the canonical ESYT architecture (ER hairpin, SMP domain, multiple C2 domains) — preserve all elements. • Calcium-binding-deficient rescue: C2 domain Ca²⁺-binding aspartate mutations affect calcium-regulated tethering. • Functional readout: rescue should restore ER-PM contact site formation and calcium-regulated lipid transfer. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying GBA1 in a high-transfection-efficiency platform for systematic structure-function studies. The Knockout line is the standard tool for asking whether GBA1 is required for glucosylceramide hydrolysis — GBA1 is the principal lysosomal β-glucocerebrosidase, with crucial implications for Gaucher disease and GBA1-associated PD risk. Overexpression is useful for studying GBA1 in heterologous expression contexts. For systematic GBA1 biochemistry, the EDITGENE GBA1 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies of this lysosomal hydrolase. This product complements the parallel GBA1 Knockout in HeLa (also available); HEK293 is preferred for biochemistry and overexpression-based rescue, HeLa for imaging-based lysosomal studies. Rescue with wild-type or patient-derived mutant GBA1 enables disease genotype-function studies. The knockout is a critical specificity control for ERT and pharmacological chaperone therapy specificity testing.

Yes. GBA1 rescue experiments in HEK293 are well-suited for systematic biochemistry: • Construct design: same considerations as GBA1/HeLa rescue — preserve signal peptide processing and lysosomal trafficking. • High-throughput rescue: HEK293's transfection efficiency supports systematic patient mutation library screening. • Pharmacological chaperone studies: rescue interpretation considers ambroxol-dependent folding rescue versus genetic rescue. • Functional readout: rescue should restore GCase activity measured by 4-MU-Glc cleavage assay. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ERBB2 (HER2, Neu)'s role as the principal heterodimerization partner of the EGFR/ERBB family or modeling HER2-amplified breast cancer and HER2-targeted therapy. The Knockout line is the standard tool for asking whether HER2 is required for these processes — ERBB2 is the orphan receptor of the EGFR family (no high-affinity ligand identified) that preferentially heterodimerizes with EGFR (ERBB1), ERBB3, and ERBB4 to amplify ligand-induced signaling; HER2 amplification (~20% of breast cancers, also gastric cancer, esophageal adenocarcinoma, NSCLC) is one of the most clinically actionable oncogenic events. Overexpression is useful for studying HER2 amplification effects. For HER2-targeted therapy research, the EDITGENE ERBB2 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies of HER2 and serves as a critical specificity control for HER2-targeted compound development. Rescue with wild-type, kinase-dead, or specific HER2 variants enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐⭐ trastuzumab (Herceptin), pertuzumab (Perjeta), trastuzumab emtansine (T-DM1, Kadcyla), trastuzumab deruxtecan (T-DXd, Enhertu — also active in HER2-low breast cancer), tucatinib (Tukysa), neratinib, lapatinib, and emerging HER2-targeted ADC/bispecific antibody/CAR-T strategies — HER2 is one of the most validated cancer drug targets.

Yes. HER2 rescue experiments are well-established for cancer drug development: • Construct design: use a codon-modified ERBB2 sequence with a small intracellular C-terminal tag (FLAG, HA). HER2 has extracellular four-domain region (subdomains I-IV, with pertuzumab binding subdomain II and trastuzumab binding subdomain IV), single transmembrane span, juxtamembrane region, and intracellular kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane HER2 expression before therapy specificity testing. • Kinase-dead rescue: K753A in the ATP-binding lysine abolishes catalytic activity. • Trastuzumab-resistant rescue: subdomain IV epitope mutations confer trastuzumab resistance for on-target Herceptin validation. • Functional readout: rescue should restore HER2 heterodimerization with EGFR/ERBB3/ERBB4, downstream PI3K-AKT/MAPK signaling, and HER2-targeted therapy sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FLT3 (FMS-like tyrosine kinase 3, CD135)'s role as a hematopoietic receptor tyrosine kinase or modeling FLT3-mutant acute myeloid leukemia (AML). The Knockout line is the standard tool for asking whether FLT3 is required for these processes — FLT3 is a class III receptor tyrosine kinase (with KIT, PDGFR, FMS, FLT1) activated by FLT3 ligand (FLT3LG), driving hematopoietic stem/progenitor cell proliferation; FLT3 is among the most frequently mutated genes in AML, with ITD (internal tandem duplication, ~25% AML) and TKD (tyrosine kinase domain, ~10% AML) mutations driving constitutive activation. Overexpression of mutant FLT3 (FLT3-ITD, FLT3-D835Y) is useful for studying gain-of-function AML mutations. For AML research, the EDITGENE FLT3 Knockout in HEK293 is highly informative — HEK293 supports systematic structure-function studies of FLT3. Rescue with wild-type, FLT3-ITD, FLT3-D835Y, or kinase-dead FLT3 enables comprehensive AML disease mechanism studies. The knockout is a critical specificity control for ⭐⭐ midostaurin (Rydapt, FDA-approved for FLT3-mutant AML 2017), gilteritinib (Xospata, FDA-approved 2018), quizartinib (Vanflyta, FDA-approved 2023), crenolanib, and emerging FLT3-targeted AML drug development.

Yes. FLT3 rescue experiments are well-established for AML drug development: • Construct design: use a codon-modified FLT3 sequence with a small intracellular C-terminal tag (FLAG, HA). FLT3 has extracellular five Ig-like domains (FLT3LG binding), transmembrane span, juxtamembrane region, and split tyrosine kinase domain (TKD1, kinase insert, TKD2) — preserve all elements. • Surface localization validation: confirm plasma membrane FLT3 expression before functional assays. • Kinase-dead rescue: K644A mutation in the ATP-binding lysine abolishes catalytic activity. • AML mutation rescue: FLT3-ITD (internal tandem duplication in juxtamembrane region) and FLT3-D835Y (TKD activation loop) mutations enable AML genotype-function studies and FLT3 inhibitor sensitivity testing. • Functional readout: rescue should restore FLT3LG-induced phospho-FLT3 and downstream STAT5/MAPK/PI3K activation. HEK293 transduces efficiently with lentivirus and supports systematic FLT3 mutation analysis for AML drug development.

The choice depends on whether you are studying FOLH1 (PSMA, prostate-specific membrane antigen, GCPII)'s role as a folate hydrolase/glutamate carboxypeptidase or modeling its applications in prostate cancer PET imaging and radioligand therapy. The Knockout line is the standard tool for asking whether PSMA is required for these processes — FOLH1 (PSMA) is a type II transmembrane glycoprotein with extracellular folate hydrolase and N-acetylated α-linked acidic dipeptidase (NAALADase) activity; PSMA is highly overexpressed in prostate cancer cells and is the molecular target of all clinical PSMA-PET imaging and radioligand therapy. Overexpression is useful for studying PSMA in heterologous expression contexts. For prostate cancer therapeutic research, the EDITGENE FOLH1 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic PSMA-targeted compound development. Rescue with wild-type or enzymatically-dead PSMA enables structure-function studies. The knockout is a critical specificity control for ⭐⭐ Lu-177-PSMA-617 (lutetium-177-vipivotide tetraxetan, Pluvicto/Novartis, FDA-approved 2022 for metastatic castration-resistant prostate cancer), Lu-177-PSMA-I&T, and emerging PSMA-targeted radioligand therapies including diagnostics (68Ga-PSMA-11/Locametz, F-18-DCFPyL/Pylarify for PSMA-PET) and therapeutics.

Yes. PSMA rescue experiments are well-established for prostate cancer therapeutic research: • Construct design: use a codon-modified FOLH1 sequence with a small intracellular C-terminal tag (FLAG, HA). PSMA is a type II transmembrane glycoprotein — N-terminal short cytoplasmic tail, single transmembrane span, large extracellular catalytic domain with C-terminal exopeptidase activity — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining before PSMA-targeted compound testing. • Enzymatically-dead rescue: catalytic glutamate mutations abolish folate hydrolase/NAALADase activity. • Functional readout: rescue should restore PSMA-targeted compound (Lu-177-PSMA-617, 68Ga-PSMA-11) cellular binding and uptake. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CTLA4 (cytotoxic T-lymphocyte-associated antigen 4, CD152)'s role as the prototypical immune checkpoint or modeling CTLA-4-targeted cancer immunotherapy. The Knockout line is the standard tool for asking whether CTLA-4 is required for these processes — CTLA-4 is a transmembrane immune checkpoint receptor expressed on activated T cells and constitutively on regulatory T cells (Tregs); CTLA-4 binds CD80/CD86 on antigen-presenting cells with much higher affinity than the co-stimulatory CD28, sequestering these ligands and downregulating T cell activation; CTLA-4 also trans-endocytoses CD80/CD86 from APCs via Treg function. Overexpression is useful for studying CTLA-4 in heterologous expression contexts. For immune checkpoint research, the EDITGENE CTLA4 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies of CTLA-4 and serves as a critical specificity control for anti-CTLA-4 antibody development. Rescue with wild-type or trafficking-deficient CTLA-4 enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ ipilimumab (Yervoy, FDA-approved 2011 — the first immune checkpoint inhibitor; melanoma, NSCLC, RCC, HCC, MSI-H CRC indications), tremelimumab (FDA-approved for HCC and NSCLC), and emerging next-generation CTLA-4-targeted strategies — anti-CTLA-4 therapy initiated the cancer immunotherapy revolution (James Allison's 2018 Nobel Prize).

Yes. CTLA-4 rescue experiments require attention to transmembrane checkpoint architecture: • Construct design: use a codon-modified CTLA4 sequence with a small intracellular C-terminal tag (FLAG, HA). CTLA-4 has extracellular IgV-like CD80/CD86-binding domain, single transmembrane span, and intracellular GYFIN motif (β-arrestin trafficking) — preserve all elements. • Surface localization validation: confirm plasma membrane localization by cell surface staining before functional assays — CTLA-4 is mostly intracellular at steady state. • Ligand-binding-deficient rescue: extracellular domain mutations abolish CD80/CD86 binding. • Trafficking-deficient rescue: GYFIN motif mutations affect endocytic trafficking. • Functional readout: rescue should restore CD80/CD86 binding and CTLA-4-mediated immune checkpoint function in appropriate immune cell co-culture systems. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for ipilimumab/tremelimumab specificity testing.

The choice depends on whether you are studying EPHA2's role as a class A Eph family RTK or modeling its functions in cancer biology and emerging EPHA2-targeted therapeutic strategies. The Knockout line is the standard tool for asking whether EPHA2 is required for these processes — EPHA2 is the most-characterized EphA subfamily receptor with established roles in tumor angiogenesis, cancer cell migration, and emerging functions as a cancer therapy target; EPHA2 binds ephrin-A1 with high affinity, and EPHA2 overexpression correlates with poor prognosis in multiple cancers. Overexpression is useful for studying EPHA2 gain-of-function effects. For cancer biology research, the EDITGENE EPHA2 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies. Rescue with wild-type or kinase-dead EPHA2 is the standard specificity control. The knockout is a critical specificity tool for anti-EPHA2 antibodies, EPHA2-targeted ADCs, and emerging Eph-targeted cancer therapeutics — EPHA2 has been explored as a target for ADC development in multiple cancer types.

Yes. EPHA2 rescue experiments are well-established for cancer research: • Construct design: use a codon-modified EPHA2 sequence with a small intracellular C-terminal tag (FLAG, HA). EPHA2 has the canonical Eph architecture — preserve all elements. • Surface localization validation: confirm plasma membrane localization before ephrin-A binding studies. • Kinase-dead rescue: K646A mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore ephrin-A1-induced phospho-EPHA2 (Y594, Y772) and downstream signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying EGF (epidermal growth factor)'s role as the prototypical EGFR ligand or its functions in autocrine/paracrine signaling. The Knockout line is the standard tool for asking whether EGF is required for autocrine EGFR signaling — EGF is a 53-amino-acid secreted growth factor (processed from the larger pre-pro-EGF precursor) that binds EGFR (ERBB1) with high affinity, triggering receptor dimerization, autophosphorylation, and downstream PI3K-AKT and RAS-MAPK signaling. Overexpression is useful for studying EGF gain-of-function effects. For EGF-EGFR pathway research, the EDITGENE EGF Knockout in HEK293 enables study of autocrine EGF production. Rescue with wild-type or receptor-binding-deficient EGF enables structure-function studies. The knockout is valuable for studying autocrine EGF signaling, EGFR-targeted cancer therapeutic specificity (cetuximab, panitumumab anti-EGFR antibodies; gefitinib, erlotinib, osimertinib EGFR-TKIs), and emerging EGF-modulating therapeutic strategies.

Yes. EGF rescue experiments require attention to secreted growth factor processing: • Construct design: EGF is processed from a large pre-pro-EGF precursor (1207 aa) into the mature 53-aa secreted polypeptide — use untagged EGF and quantify secreted form by ELISA, or use precursor with internal tag carefully placed away from the EGF domain. • Secretion validation: confirm conditioned media EGF levels by ELISA before functional assays. • Receptor-binding-deficient rescue: EGFR-binding residue mutations in the mature EGF abolish EGFR activation. • Functional readout: rescue should restore conditioned-media EGF levels and autocrine EGFR activation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.